NIVES study: A phase II trial of nivolumab (NIVO) plus stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC).
2018 ◽
Vol 36
(15_suppl)
◽
pp. TPS4602-TPS4602
◽
2009 ◽
Vol 7
(2)
◽
pp. 437-438
◽